Peers of Spyre Therapeutics Inc (SYRE)
Side-by-side comparison
Health Care · Biotechnology
Enterprise value divided by trailing twelve-month free cash flow. Values the entire business on cash available after reinvestment.
Latest EV/FCF
-30.64x
As of Oct 9, 2026
Beyond EV/FCF, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | EV/FCF |
|---|---|
| Oct 9, 2026 | -30.64x |
| Oct 8, 2026 | -28.19x |
| Oct 7, 2026 | -28.59x |
| Oct 6, 2026 | -28.28x |
| Oct 5, 2026 | -33.60x |
| Oct 2, 2026 | -33.80x |
| Oct 1, 2026 | -32.42x |
| Sep 30, 2026 | -32.04x |
EV/FCF = Enterprise Value / Free Cash Flow (TTM). Enterprise Value = Market Cap + Total Debt − (Cash & Short-Term Investments + Long-Term Investments).
EV/FCF is especially insightful for capital-intensive businesses.
Read the general EV/FCF definition, formula, and analyst usage guide.
EV/FCF guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
Side-by-side comparison